# A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation

> **NCT05776108** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 24 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Cabotegravir IR Formulation (reference)
- **DRUG:** Cabotegravir DT Formulation (test 1)
- **DRUG:** Cabotegravir DT Formulation (test 2)

## Key facts

- **NCT ID:** NCT05776108
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-23
- **Primary completion:** 2023-06-08
- **Final completion:** 2023-06-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05776108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05776108, "A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05776108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*